NCT Number: NCT00233376
Computerized Decision Support System for Antibiotic Treatment
We developed a computerized decision support system for prescription of antibiotics to inpatients. The purpose of the study is to assess the performance of the system in different wards, in three different hospitals, in three countries.
Looking for future studies?
Notify MeKey information
Conditions
Age range
16 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Department of Clinical Microbiology and Hospital Hygeine, Freiburg University Hospital, Freiburg im Breisgau, Germany
About this study
Antibiotic treatment for suspected moderate to severe bacterial infections is usually initiated empirically, prior to identification of the causative pathogen. Appropriate treatment, that is matching in-vitro susceptibilities of subsequently isolated pathogens, reduces the overall fatality rate of severe infections with adjusted odds ratios varying between 1.6 and 6.9. In the same studies, 20-50% of patients were given inappropriate empirical antibiotic treatment.
We developed a computerized decision support system (TREAT) based on a causal probabilistic network to improve antibiotic treatment of inpatients. The aims of the system were to improve the rate of appropriate antibiotic treatment, thereby reducing mortality, and to route antibiotic use towards ecologically economical antibiotics as determined by local resistance profiles. The system can be calibrated to different locations.
The TREAT system was tested in a multi-center observational cohort study. The study proved the system safe and effective. TREAT prescribed appropriate antibiotic treatment to 70% of patients, 58% of whom were treated appropriately by physicians. TREAT used a narrow antibiotic formulary and at lower costs, mainly lowering costs assigned by the model to future resistance. The system performed well in three different countries (Israel, Italy and Germany).
We then proceeded to assess the effect of TREAT on the management of inpatients in these sites in a cluster randomized controlled trial. We used wards as the unit of randomization to avoid contamination through education of users by the system, and to benefit from the interaction of TREAT with the ward as a whole.
Comparison: the TREAT system was installed in intervention wards and its use was offered to physicians at the time of empirical antibiotic treatment. Physicians were asked to inspect TREAT's result interface. The final choice of antibiotic treatment was theirs. Control wards had no access to the system. We assessed outcomes in intervention vs. control wards with regard to patient outcomes, appropriateness of antibiotic treatment and antibiotic costs.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients from whom blood cultures were drawn.
- Patients prescribed antibiotics (not for prophylaxis).
- Patients fulfilling sepsis diagnostic criteria.
- Patients with a focus of infection.
- Patients with shock compatible with septic shock.
- Patients with febrile neutropenia
Exclusion criteria
- HIV positive patients with a current (suspected or identified) opportunistic disease and/or AIDS defining illness currently or within the past six months
- Organ or bone marrow transplant recipients
- Children <18 years; suspected travel infections or tuberculosis
- Pregnant women
- Re-entries
Treatment and study plan
Distribution of local antibiotic guidelines
BehavioralPrimary outcomes
-
Appropriate antibiotic treatment
Secondary outcomes
-
Overall 30-day mortality
-
Durations of fever
-
Duration of hospital stay
-
Antibiotic use
-
Antibiotic costs
-
Adverse events
Sponsors and collaborators
Lead sponsor
Rabin Medical Center
Other
Collaborators
- Eu Fifth Framework IST
Registry information
Official study title
Improving Empirical Antibiotic Treatment Using TREAT,a Computerized Decision Support System. Cluster Randomized Trial
Important dates
- Study start
- 2004
- Study completion
- 2004
- First posted
- Oct 5, 2005
- Registry last updated
- Jul 18, 2006
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
An Open-label, Randomized, Single Period, Parallel-Cohort Study To Evaluate Serum and Pulmonary Pharmacokinetics Following Single and Multiple Dose Administration of Intravenous GSK2251052 in Healthy Adult Subjects
NCT01267968
Community-Acquired Infections, Community-acquired Infection
Minneapolis, Minnesota, United States
View Trial DetailsGSK2251052 Mass Balance in Healthy Adult Subjects
NCT01475695
Community-Acquired Infections, Community-acquired Infection
Zuidlaren, Netherlands
View Trial DetailsStudy Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia
NCT00081575
Bacterial Infections, Bacterial Infections and Mycoses
View Trial DetailsApplication Effect Analysis of Bundle Nursing Intervention
NCT07656363
Cross Infection, Disease Attributes
Qinhuangdao, Hebei, China
View Trial Details